Lupin Receives US FDA Approval For Cefprozil Suspension

BSE: 500257	NSE: LUPIN	REUTERS: LUPN.BO	BLOOMBERG: LPC IN

Mumbai, December 20, 2005: Lupin Ltd. today announced that it has received US FDA approval for its Abbreviated New Drug Application (ANDA) for Cefprozil Oral Suspension, 125 mg/5 ml and 250 mg/5 ml. Cefprozil is the generic equivalent of Bristol Myers Squibb's Cefzil®. The suspension market in the US is USD 119 million as per IMS MAT June 2005 data. Earlier this month, the Company received approval from the US FDA for Cefprozil tablets.

Speaking of the approval, Chairman Dr. D B Gupta said: "The timely approval of this ANDA now enables us to offer both the tablets and the powder for suspension which is essential for the product's success. Together the Cefzil brand clocks in at USD 236 million and we look forward to capturing a profitable market share post patent expiry on December 23, 2005."

This is Lupin's tenth ANDA approval by the US FDA till date and the fifth in this financial year.

About Lupin

Headquartered in Mumbai, Lupin (http:/www.lupinworld.com) develops, manufactures and markets generic intermediates, active pharmaceutical ingredients and finished dosages. Its FY 2004-05 revenues were Rs.12 billion. 11 of Lupin's plant have been approved by the US FDA and two facilities have been approved by the UK MHRA

For further information contact:
Raju Kane
The Source
Mobile: +91 98200 45656
E-mail: **rajukane@sourcepr.com**